accountTargeted Agent in a Phase 3 Trial in Advanced RCC NEW YORK, May 18, 2011 (BUSINESS WIRE) -- Pfizer Inc. today announced data from the pivotal Phase 3 AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma (RCC),...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Pfizer Presents New Phase 3 Data Showing Axitinib Significantly Extended Progression-Free Survival Compared With Sorafenib In Patients With Previously-Treated Advanced Renal Cell Carcinoma
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account